Literature DB >> 3547621

Anaerobic infections and Clostridium difficile colitis emerging during antibacterial therapy.

S M Finegold.   

Abstract

Almost all cases of Clostridium difficile-related pseudomembranous colitis are related to antimicrobial therapy. Virtually all antibacterial agents have been implicated, notable exceptions being vancomycin and parenterally administered aminoglycosides. The most prominent causes of colitis are ampicillin, clindamycin and various cephalosporins. In general, this complication is related to suppression of indigenous flora and overgrowth of C. difficile. In the case of ampicillin, however, C. difficile is always susceptible. Beta-lactamase production by elements of the bowel flora leads to destruction of ampicillin and subsequently to increased counts of C. difficile and colitis. Much less well-appreciated, and much less studied, is overgrowth and subsequent infection by other types of anaerobic bacteria. Superinfection by anaerobes may follow the use of "intestinal antiseptics" such as oral neomycin; indeed, that is the rationale for the current practice in the U.S. of combining erythromycin or tetracycline with the oral aminoglycoside. Superinfection with anaerobes may also follow systemic administration of various antimicrobial compounds. Such superinfections may involve any site in the body, although sepsis and intraabdominal infection have been noted most commonly; all major types of anaerobes have been involved. A wide variety of antimicrobial compounds has been implicated in predisposing to anaerobic infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3547621

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  9 in total

1.  Probiotics to prevent the need for, and augment the use of, antibiotics.

Authors:  Gregor Reid
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

2.  An epidemiologic postmarketing surveillance study of prescription acne medications.

Authors:  D P Facklam; J S Gardner; G L Neidert; M M Westland
Journal:  Am J Public Health       Date:  1990-01       Impact factor: 9.308

3.  Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

Authors:  A V Boddy; G W Elmer; L V McFarland; R H Levy
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

4.  Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links.

Authors:  Johann Peltier; Pascal Courtin; Imane El Meouche; Ludovic Lemée; Marie-Pierre Chapot-Chartier; Jean-Louis Pons
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

5.  New selective medium for isolating Clostridium difficile from faeces.

Authors:  S T Aspinall; D N Hutchinson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

6.  Comparison of media for screening of diarrheic stools for the recovery of Clostridium difficile.

Authors:  P C Iwen; S J Booth; G L Woods
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

Review 7.  Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.

Authors:  Masako Mizusawa; Shira Doron; Sherwood Gorbach
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

Review 8.  Role of oral antibiotics for prophylaxis against surgical site infections after elective colorectal surgery.

Authors:  Shamir O Cawich; Sachin Teelucksingh; Samara Hassranah; Vijay Naraynsingh
Journal:  World J Gastrointest Surg       Date:  2017-12-27

9.  Effects of treatment with antimicrobial agents on the human colonic microflora.

Authors:  Fatemeh Rafii; John B Sutherland; Carl E Cerniglia
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.